Therapix Biosciences (TRPX) is an Israel-headquartered emerging specialty pharmaceutical company developing unique cannabinoid technologies in treatment of central nervous system (CNS) disorders. TRPX is engaged in two development programs based on repurposing an FDA approved synthetic cannabinoid Marinol (dronabinol). The first program is THX-TS01 for the treatment of symptoms related to Tourette Syndrome (TS), and the second is THX-ULD01 and targets the underserved market of mild cognitive impairment (MCI).
TRPX has filed for Orphan Drug Designation (ODD) for its THX-TS01 formulation for TS, and intends to pursue ODD in Europe. For both development programs, TRPX is pursuing a 505(b)(2) regulatory strategy for FDA approval. TRPX is also developing unique cannabinoid delivery technologies to improve drug administration, including nasal and sublingual delivery methods for THC with formulations designed to increase efficacy compared with standard oral administration. Approvals for indications such as TS and MCI may lead to applications in several additional therapeutic indications, including pain, cancer, anti-inflammatory, dermatology, and psychiatric disorders.